West China Hospital starts Phase 2 vericiguat trial for calcific aortic valve stenosis with Bayer
The VERIFICATION study will test whether Bayer's sGC stimulator vericiguat can slow progression of mild-to-moderate aortic valve calcification.
West China Hospital registered one new interventional trial in collaboration with Bayer.
- "Vericiguat for the Inhibition of Calcific Aortic Valve Stenosis Progression" (VERIFICATION, NCT07715279) is a Phase 2, randomized, double-blind, placebo-controlled study testing oral vericiguat in patients with mild-to-moderate calcific aortic valve stenosis. The trial is expected to enroll approximately 238 participants across roughly 19 hospitals in China1, with the primary endpoint being change in aortic valve calcium score from baseline to 24 months compared with placebo1. The record lists an actual start date of 2026-09-24 and estimated primary completion of 2029-10-31.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.